Blumenthal S A, Moses A M
Endocrinology. 1985 Feb;116(2):660-4. doi: 10.1210/endo-116-2-660.
Phosphorylase a activity was measured in hepatocytes from fed rats, some of which received ip chlorpropamide injections for 5 days preceding death (20 mg/100 g BW X day for 5 days). Chlorpropamide treatment significantly depressed basal phosphorylase a activity and lessened the increments in the activity of this enzyme induced by 10(-10) -10(-8) M glucagon and arginine vasopressin. The reductions in phosphorylase a activity after treatment with chlorpropamide were more than sufficient to explain the accompanying decreases in hepatic glucose production. Since glucagon and arginine vasopressin stimulate alternate pathways of phosphorylase activation and since chlorpropamide antagonizes both hormones, it is likely that the drug acts at or distal to the intracellular site (phosphorylase kinase) at which the two activation pathways converge.
在喂食大鼠的肝细胞中测定磷酸化酶a活性,其中一些大鼠在处死前5天接受腹腔注射氯磺丙脲(20mg/100g体重×天,共5天)。氯磺丙脲处理显著降低了基础磷酸化酶a活性,并减少了由10(-10)-10(-8)M胰高血糖素和精氨酸加压素诱导的该酶活性的增加。氯磺丙脲处理后磷酸化酶a活性的降低足以解释伴随的肝葡萄糖生成减少。由于胰高血糖素和精氨酸加压素刺激磷酸化酶激活的替代途径,且氯磺丙脲拮抗这两种激素,因此该药物可能作用于两条激活途径汇聚的细胞内位点(磷酸化酶激酶)或其远端。